• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients

byJohan PushaniandSze Wah Samuel Chan
September 19, 2022
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in PD-L1 unselected non-small-cell lung cancer patients who underwent complete resection.

2. Adverse events of grades 3 or higher occurred slightly more often in the pembrolizumab arm, with the most common ones being hypertension and pneumonia in the pembrolizumab arm and hypertension and weight gain in the placebo arm.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Pembrolizumab (a programmed cell death 1 inhibitor) is the standard of care for metastatic non-small-cell lung cancer (NSCLC) due to its clinical benefit and tolerable safety profile. This study explored pembrolizumab as an adjuvant therapy for completely resected NSCLC; this is the 2nd interim analysis of the study. Patients who underwent complete resection were randomly assigned to receive either pembrolizumab or placebo as adjuvant therapy. Randomization was stratified by disease stage and PD-L1 tumour proportion score (TPS) among other factors. Median disease-free survival (DFS) was higher in the pembrolizumab arm in the overall population but was not reached in either arm of the TPS>50% population. Overall survival data is still immature at the time of this interim analysis. Adverse events of grades 3 or higher occurred slightly more frequently in the pembrolizumab arm, with the most common in the pembrolizumab arm being hypertension and pneumonia, and hypertension and weight gain in the placebo arm. Serious adverse events occurred slightly more frequently in the pembrolizumab arm, as did treatment-related adverse events (TRAEs) that led to death. The strengths of this study are its limited bias given the design and that the results of the study support the current evidence of immune checkpoint inhibitors as adjuvant therapy. Limitations to this study include a predominantly male population and the lack of biomarker use such as EGFR and ALK. Median DFS in the TPS>50 subgroup was also not reached, despite relative benefit of pembrolizumab increasing with increased PD-L1 expression, suggesting that a longer follow-up is also needed. Overall, adjuvant pembrolizumab is a potentially viable treatment option for stage IB-IIIA NSCLC patients who underwent complete resection, regardless of their PD-L1 expression.

Click to read the study in The Lancet Oncology

Relevant Reading: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

In-Depth [randomized control trial]: This international phase III clinical trial included 1177 patients with metastatic NSCLC who underwent complete resection. Patients were randomly assigned 1:1 to receive either pembrolizumab or placebo as adjuvant therapy; 590 were in the former arm and 587 were in the latter arm. Median DFS in pembrolizumab and placebo arms for the overall population was 53.6 months (95% confidence interval [CI], 39.2 to not reached) and 42.0 months (31.3 to not reached), respectively (hazard ratio [HR], 0.76; 95% CI, 0.63 to 0.91; P=0.0014). Median DFS for the TPS>50% population was not reached in the pembrolizumab arm (95% CI, 44.3 to not reached) or the placebo arm (95% CI, 35.8 to not reached) (HR, 0.82; 95% CI, 0.57 to 1.18; P=0.14). Adverse events of grade 3 or higher occurred in 34% of patients in the pembrolizumab arm and in 26% in the placebo arm. Hypertension (6%) and pneumonia (2%) were the most common in the pembrolizumab arm, in comparison to hypertension (6%) and increased weight (2%) in the placebo arm. Serious adverse events occurred in 24% and 15% of patients, respectively. TRAEs that led to death occurred in 1% and 0% of patients, respectively. Immune-mediated events and transfusion reactions occurred in 39% of patients and 13% of patients, respectively. Overall, adjuvant pembrolizumab significantly increased DFS in PD-L1 unselected, completely resected NSCLC patients.

RELATED REPORTS

Adjuvant pembrolizumab improved distant-metastasis free survival and lowered risk of recurrence in melanoma patients

#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer

Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adjuvant immunotherapynon-small cell lung cancer (NSCLC)Pembrolizumab
Previous Post

Bihormonal artificial pancreas effective for post total pancreatectomy patients

Next Post

Magnesium for the prevention of cerebral palsy [Classics Series]

RelatedReports

Patients with late stage melanoma remain at risk for further primary melanoma
Oncology

Adjuvant pembrolizumab improved distant-metastasis free survival and lowered risk of recurrence in melanoma patients

October 24, 2022
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
StudyGraphics

#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer

October 19, 2022
Patient Basics: Thyroid Cancer
Oncology

Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer

December 28, 2022
Patient Basics: Squamous Cell Carcinoma of the Lung
Oncology

Toripalimab addition to chemotherapy showed improved survival in advanced stage non-small-cell lung cancer

October 17, 2022
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Magnesium for the prevention of cerebral palsy [Classics Series]

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Neoadjuvant celmiplimab is associated with pathologic response in cutaneous squamous cell carcinoma

American College of Physicians releases principles to guide patient partnership in health care

Summary Elixhauser score interally validated for mortality prediction in older adults

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options